Dr. John Shiver is Sr. Vice President, Research and Development with Sanofi Pasteur since 2013. He has 22 years of vaccine research and development experience from Merck where he also led Vaccine Research for 9 years following four years as Senior Staff Fellow in the Experimental Immunology Branch of the National Cancer Institute, National Institutes of Health.
Dr. Shiver has gained international recognition in the scientific community for his leadership of Merck’s novel HIV vaccine research program. He is the author of more than 150 articles that have been published in leading scientific journals, including 19 in the high impact journals Science, Nature, Cell, and the Proceedings of the National Academy of Sciences. In addition, Dr. Shiver is a co-author of 68 awarded patents covering his contributions in the field of novel vaccine development. He is a Fellow of the American Academy of Microbiology, International Society for Vaccines, and was recognized by the Financial Times.
Dr. Shiver is a member of the Executive Board of the International Society of Vaccines, the NIH HIV-1 Vaccine Testing Network Laboratory Science Advisory Committee, Okairos Scientific Advisory Board, and the Scientific Advisory Board of the Seattle Biomedical Research Institute, and has served previously on the Aeras Global TB Vaccine Foundation Immunology Advisory Group. He has served as an Editorial Board Member for the Journal of Virology and Drug Discovery Today: Disease Mechanisms. He is an Adjunct Professor at the University Of Pennsylvania College Of Medicine.
After graduating with a B.S. degree in Chemistry/Mathematics from Wofford College, Dr. Shiver received a Ph.D. in physical Chemistry from the University of Florida, and completed a postdoctoral fellowship in Biophysics at Purdue University.